ANN ARBOR - A University of Michigan startup that's developing a non-invasive way to remove diseased tissue from cancer patients using high-intensity ultrasound has attracted $8.3 million in Series B financing. The investment will help advance clinical trials of HistoSonics' Robotic Assisted Sonic Therapy—an innovative tissue-destruction technology targeted for liver cancer and other